



Navinci to attend AACR and accelerate the pre-launch of new multiplex kit

Uppsala, Sweden – April 15, 2026 - Navinci today announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 19-22. At booth #1917, Navinci will highlight its latest advancements, including accelerating the pre-launch of its highly anticipated multiplex kit, Omni, as well as the presentation of two scientific posters developed in collaboration with leading partners.

At the event, Navinci will pre-launch its new multiplex kit, Omni, which will be available for shipment starting in May. This technology will enable researchers to simultaneously detect multiple protein–protein interactions, phosphorylation events and single protein targets within a spatial context. Researchers can design fully customized panels using Navinci’s library of validated targets, or choose from a range of pre-validated panels covering key research areas. This technology opens the door to powerful new possibilities for mapping protein function and networks, to better understand health, disease progression and treatment prediction

Navinci will also be represented in two collaborative posters at AACR, showcasing cutting-edge applications of its technology. One poster, titled **‘Development of a proximity ligation-imaging mass cytometry platform for spatially resolved immune checkpoint analysis’**, demonstrates integration of Navinci’s technology with imaging mass cytometry, in collaboration with Uppsala University. A second poster, titled **‘Novel tools for spatial profiling of protein glycosylation in cancer biology’**. from Vector Laboratories, highlights the [Glysite Explorer](#), a novel approach to studying protein glycosylation. Attendees are invited to visit Navinci at booth #1917 to meet the team, learn more about Omni, explore partnership opportunities, and discuss how Navinci’s solutions can support their research goals.

For more information about the posters or to schedule a meeting during AACR, please visit our [AACR 2026 homepage](#) or [contact us](#).

For further information, please contact:

Jenny Sundqvist, CEO
E-mail: jenny.sundqvist@navinci.se

Kjell Ruth, CCO
E-mail: kjell.ruth@navinci.se



About Navinci

Navinci is a Swedish biotech company specializing in developing innovative solutions for studying *in situ* protein expression and interactions. With a focus and a strong legacy in developing *in situ* proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.